Skip to main content
CriticalFDAfda-Z-1201-2021OTHER

Valiant Navion Thoracic Stent Graft System. For endovascular repair of lesions in the descending thoracic aorta (DTA).

⚠ Critical Alert — Stop Using Immediately

This product has been flagged with severe risks (other). Stop using it now and contact the brand or FDA for a refund, repair, or replacement.

Units Affected
33,430
Recall Date
February 12, 2021
Issuing Agency
Hazard
Other

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-Z-1201-2021.

Due to the presence of type IIIb endoleaks, stent fractures, and stent ring enlargement.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-Z-1201-2021.

Recall ongoing. Follow firm instructions.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Medtronic Vascular, Inc. or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-Z-1201-2021.

Medtronic Vascular, Inc.

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Medtronic Vascular, Inc. Recall FAQ

Medtronic Vascular, Inc. is the subject of a medical implants safety report: Valiant Navion Thoracic Stent Graft System. For endovascular repair of lesions in the descending thoracic aorta (DTA).. The notice was published on February 12, 2021 by the U.S. Food and Drug Administration (FDA). Approximately 33,430 units are potentially affected.